REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.64
Bid: 3.30
Ask: 3.64
Change: -0.33 (-8.68%)
Spread: 0.34 (10.303%)
Open: 3.70
High: 3.70
Low: 3.64
Prev. Close: 3.80
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on sugarcane in Brazil

30 Jul 2018 07:00

RNS Number : 0790W
Plant Health Care PLC
30 July 2018
 

 

 

30 July 2018

PLANT HEALTH CARE plc

 

("Plant Health Care" or the "Company")

 

 

Update on sugarcane in Brazil

 

Plant Health Care®, a leading provider of novel patent-protected biological products to global agriculture markets, provides the following update on Harpin αβ launch in Brazil.

 

 

Highlights

- Harpin αβ applied in sugarcane in Brazil; demonstration plot yield increase of 20% or more.

- Harpin αβ was launched in Brazil sugarcane in February 2018 through Coplacana under the brand name H2Copla. Grower feedback has been strong.

- Since the launch of H2Copla in February 2018, the product has generated revenue of $400k. The Company expects to generate at least as much revenue from H2Copla in the second half of 2018.

- The Company is now planning for the launch of Harpin αβ in coffee, which has similar potential to sugarcane.

 

With 10 million hectares planted, Brazil sugarcane is an important target for Plant Health Care. The Company has been developing Harpin αβ for use in this crop. Trials have been conducted in both ratoon cane (i.e. cane which grows back after harvest) and newly planted cane (normal practice is to take five crops from ratton cane, then plant again). Trials conducted on behalf of the Company in 2018 showed that single applications of a low dose (100 g per Ha) at six to eight weeks after harvest, significantly increased the yield of ratoon cane (10-29%) in ratoon cane. Moreover, it is possible that the ratoon crop may be extended from five to six years, which is a material cost reduction, especially when sugar prices are low. Trials also indicated that newly planted cane responds well to applications of Harpin αβ.

 

Based on these promising results, as announced on 16 July 2018, the Company launched a Harpin αβ product with Coplacana, a leading sugarcane co-operative in Brazil, for their exclusive use of the H2Copla brand in sugarcane. Coplacana services more than 70% of the sugarcane hectares in Sao Paolo state, where more than 5 million hectares of the crop are grown. Demonstration trials with Coplacana have shown impressive results, with an average yield increase of over 20%.

 

H2Copla was launched in February 2018 and the product has received very positive grower feedback. The launch quantities have been largely sold and the Company expects to make further sales during the second half of 2018. We confidently expect sales in Brazilian sugarcane to build in the second half of 2018 and over the coming years.

 

Arnaldo Bortoletto, President of Coplacana, said "We continue to have excellent field results with H2Copla, with good grower feedback and we expect strong demand for H2Copla in the second half of 2018".

 

Jeff Tweedy, Commercial Head, Americas for Plant Health Care, said: "We are very encouraged by the support we are receiving from Coplacana in promoting H2Copla in the field and have high expectations for future sales. The Company is now developing Harpin αβ in other crops. In 2017/18, we had most encouraging preliminary results in coffee, with both yield and quality improvements. We are now examining routes to market for Harpin αβ in this crop, with a view to launching for the 2019-2020 growing season. We see coffee as being at least as valuable a crop for the Company as sugarcane."

 

 

 

For further information, please contact:

 

Plant Health Care plc

Chris Richards, Executive Chairman and Interim CEO Tel: +1 919 926 1600

Jeffrey Tweedy, Commercial Head, Americas

 

Liberum Capital - Nomad and Broker

Clayton Bush / Chris Clarke Tel: +44 (0) 20 3100 2000

 

Arden Partners plc - Joint BrokerJohn Llewellyn-Lloyd / Dan Gee-Summons Tel: +44 (0) 20 7614 5900

 

IFC Advisory - Financial PR

Graham Herring / Miles Nolan / Zach Cohen Tel: +44 (0) 20 3934 6633

 

 

Company website: www.planthealthcare.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTBIGDRCSDBGIR
Date   Source Headline
29th May 20207:00 amRNSHolding(s) in Company
27th May 20207:00 amRNSUpdate on PHC279 2019 Field Trials
6th May 20205:12 pmRNSAnnual Report & Accounts and AGM Notice Published
1st May 20203:21 pmRNSDirector/PDMR Shareholding
24th Apr 20207:00 amRNSResults for the year ended 31 December 2019
25th Mar 20207:00 amRNSHolding(s) in Company
23rd Mar 20203:45 pmRNSHolding(s) in Company
19th Mar 20203:09 pmRNSHolding(s) in Company
16th Mar 202011:53 amRNSResults of General Meeting
11th Mar 20207:00 amRNSPHC279 Submitted for Regulatory Approval in Brazil
24th Feb 20209:18 amRNSResults of Placing and Subscription
24th Feb 20207:00 amRNSProposed Placing and Subscription
19th Feb 20207:00 amRNSBlock listing Interim Review
5th Feb 20207:00 amRNSEmploy California Registration
23rd Jan 20207:00 amRNSFirst US patent issues for PREtec peptide products
9th Jan 20207:00 amRNSBrazil Update
20th Dec 20197:00 amRNSHolding(s) in Company
19th Dec 20197:00 amRNSTrading Update
3rd Dec 20196:35 pmRNSHolding(s) in Company
22nd Nov 20192:11 pmRNSHolding(s) in Company
15th Nov 20193:42 pmRNSHolding(s) in Company
15th Nov 20193:36 pmRNSHolding(s) in Company
14th Nov 20193:36 pmRNSHolding(s) in Company
14th Nov 20197:00 amRNSHolding(s) in Company
13th Nov 20194:40 pmRNSHolding(s) in Company
13th Nov 20194:08 pmRNSHolding(s) in Company
13th Nov 20193:59 pmRNSHolding(s) in Company
13th Nov 20193:42 pmRNSHolding(s) in Company
12th Nov 20193:56 pmRNSHolding(s) in Company
6th Nov 201912:57 pmRNSInvestment in Company by Ospraie Ag Science LLC
30th Oct 20197:00 amRNSAppointment of new Board Directors
3rd Oct 20192:50 pmRNSDirector/PDMR Shareholding
30th Sep 20197:00 amRNSInterim Report ended 30 June 2019
9th Sep 20197:00 amRNSPilot production of PREtec peptides
19th Aug 20197:00 amRNSBlock listing Interim Review
15th Aug 20197:00 amRNSProgress with PREtec field trials in Brazil
5th Aug 20195:18 pmRNSHolding(s) in Company
25th Jun 20197:00 amRNSNew Distribution Agreement with Wilbur-Ellis
12th Jun 201911:05 amRNSResult of AGM
30th Apr 20194:19 pmRNSAnnual Report & Accounts and AGM Notice Published
10th Apr 20197:00 amRNSResults for the year ended 31 December 2018
27th Mar 20193:41 pmRNSHolding(s) in Company
28th Feb 20197:00 amRNSNew Technology Update
19th Feb 20197:00 amRNSBlock listing Interim Review
29th Jan 20197:00 amRNSTrading Statement
24th Jan 20195:58 pmRNSHolding(s) in Company
21st Dec 20187:00 amRNSTrading Statement
28th Nov 20187:00 amRNSNew Technology Update
21st Nov 20187:00 amRNSPlant Health Care ProAct® Wins Top Industry Award
19th Nov 20187:00 amRNSPlant Health Care to present at Mello London

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.